BioCentury | Apr 3, 2018
Distillery Therapeutics

Cancer

...B cell lymphoma; mantle cell lymphoma (MCL) Patient sample and mouse studies suggest inhibiting the pentose...
BioCentury | Dec 18, 2008
Targets & Mechanisms

Cancer's fuel duel

...glutathione, indicating that CYCS requires an oxidizing environment to induce cell death. Inhibition of the pentose...
...the oxidation level of healthy mouse neurons by treating them with peroxide or inhibiting the pentose...
...the effectiveness of chemotherapy, Mohanish Deshmukh told SciBX. This could be accomplished by inhibiting the pentose...
BioCentury | Sep 10, 2001
Company News

Genome Therapeutics management update

...Martin Williams as SVP of business development and marketing for infectious diseases, formerly VP at Pentose Pharmaceuticals Inc. WIR...
BioCentury | Jan 4, 2000
Finance

1999 M&A activity

...Merck Sibia $87.0 Catalytic Wyckoff $60.0 Corixa Ribi $59.0 NPS Pharma Allelix $53.6 V.I. Technologies Pentose...
BioCentury | Dec 13, 1999
Clinical News

Inactine: Began Phase I study

...VITX acquired the Inactine technology through its merger with Pentose Pharmaceuticals Inc. (Cambridge, Mass.). V.I. Technologies Inc. (VITX...
BioCentury | Nov 22, 1999
Company News

Pentose, V.I. Technologies deal

...The companies completed their stock merger under which Pentose shareholders received 6.4 million shares of VITX...
...shares of VITX and own 34 percent of the combined company (see BioCentury, Aug. 23). Pentose Pharmaceuticals Inc....
BioCentury | Nov 15, 1999
Clinical News

Pentose preclinical data

...Phase I testing of Inactine-treated red blood cells is expected to begin by year end. Pentose Pharmaceuticals Inc....
BioCentury | Nov 1, 1999
Company News

Pentose other research news

...and oxygen-carrying function in vitro. Pentose expects to begin Phase I testing by year end. Pentose Pharmaceuticals Inc....
BioCentury | Aug 23, 1999
Clinical News

Inactine: Began Phase I testing

...electrophilic nucleic acid binders Indication: Inactivate viruses in red blood cell concentrates for transfusion Status: Pentose...
...of its viral inactivation technology in combination with red blood cells transfused into healthy volunteers. Pentose...
BioCentury | Aug 2, 1999
Company News

Pentose, V.I. Technologies deal

...blood product viral inactivation companies will merge in a stock transaction valued at $45 million. Pentose...
...shares of VITX stock and will own 34 percent of the combined company. (Management, B8) Pentose Pharmaceuticals Inc....
Items per page:
1 - 10 of 25
BioCentury | Apr 3, 2018
Distillery Therapeutics

Cancer

...B cell lymphoma; mantle cell lymphoma (MCL) Patient sample and mouse studies suggest inhibiting the pentose...
BioCentury | Dec 18, 2008
Targets & Mechanisms

Cancer's fuel duel

...glutathione, indicating that CYCS requires an oxidizing environment to induce cell death. Inhibition of the pentose...
...the oxidation level of healthy mouse neurons by treating them with peroxide or inhibiting the pentose...
...the effectiveness of chemotherapy, Mohanish Deshmukh told SciBX. This could be accomplished by inhibiting the pentose...
BioCentury | Sep 10, 2001
Company News

Genome Therapeutics management update

...Martin Williams as SVP of business development and marketing for infectious diseases, formerly VP at Pentose Pharmaceuticals Inc. WIR...
BioCentury | Jan 4, 2000
Finance

1999 M&A activity

...Merck Sibia $87.0 Catalytic Wyckoff $60.0 Corixa Ribi $59.0 NPS Pharma Allelix $53.6 V.I. Technologies Pentose...
BioCentury | Dec 13, 1999
Clinical News

Inactine: Began Phase I study

...VITX acquired the Inactine technology through its merger with Pentose Pharmaceuticals Inc. (Cambridge, Mass.). V.I. Technologies Inc. (VITX...
BioCentury | Nov 22, 1999
Company News

Pentose, V.I. Technologies deal

...The companies completed their stock merger under which Pentose shareholders received 6.4 million shares of VITX...
...shares of VITX and own 34 percent of the combined company (see BioCentury, Aug. 23). Pentose Pharmaceuticals Inc....
BioCentury | Nov 15, 1999
Clinical News

Pentose preclinical data

...Phase I testing of Inactine-treated red blood cells is expected to begin by year end. Pentose Pharmaceuticals Inc....
BioCentury | Nov 1, 1999
Company News

Pentose other research news

...and oxygen-carrying function in vitro. Pentose expects to begin Phase I testing by year end. Pentose Pharmaceuticals Inc....
BioCentury | Aug 23, 1999
Clinical News

Inactine: Began Phase I testing

...electrophilic nucleic acid binders Indication: Inactivate viruses in red blood cell concentrates for transfusion Status: Pentose...
...of its viral inactivation technology in combination with red blood cells transfused into healthy volunteers. Pentose...
BioCentury | Aug 2, 1999
Company News

Pentose, V.I. Technologies deal

...blood product viral inactivation companies will merge in a stock transaction valued at $45 million. Pentose...
...shares of VITX stock and will own 34 percent of the combined company. (Management, B8) Pentose Pharmaceuticals Inc....
Items per page:
1 - 10 of 25